piclidenoson
Sponsor Can-fite Biopharma LTD. · listed as CANF
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
piclidenoson is a clinical-stage drug asset sponsored by Can-fite Biopharma LTD., listed as CANF. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2027 (month precision, medium confidence), tied to trial NCT06643260. The asset is in Phase 3 and currently not yet recruiting, studied in Plaque Psoriasis.
Next catalyst
Event typeREADOUT
Expected date2027-12-31
As disclosedDec 2027
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06643260
PhasePHASE3
StatusNOT_YET_RECRUITING
Lead sponsorCan-Fite BioPharma
Listed asCANF
Condition(s)Plaque Psoriasis
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.
Get the full dataset — $499 → More CANF catalysts